C85 C81 C61 C80 C15 C31 C32 C33 C34 C21 C20 C22.1 C43 C80
Conditions
Interventions
Group 1: As part of the clinically indicated PET/CT examination (routine), patients receive additional (late) PET/CT measurements 2-11 hours after the first (regular) PET/CT measurement (a maximum of
Sponsors
Universitätsklinikum Tübingen
Eligibility
Sex/Gender
All
Age
18 Years to 99 Years
Inclusion criteria
Inclusion criteria: - Justifying clinical indication for PET/CT examination, - Patients with predominantly one of the following oncological diseases: Lymphoma (Hodgkin's, non-Hodgkin's), prostate cancer, neuroendocrine tumors, patients treated with radiation oncology (esophageal cancer, head and neck tumors, lung cancer, rectal cancer, anal cancer), cholangiocellular carcinoma, malignant melanoma, CUP, - Patients able to grasp the nature and extent of pseudonymized prospective data collection, - Patients who can tolerate a waiting time of 2-11 hours between regular and late PET/CT measurements with a maximum examination time of 30-60 minutes in the PET/CT scanner, - Age =18 years, - Written informed consent from the patient.
Exclusion criteria
Exclusion criteria: - Pregnant and breastfeeding women, - Patients with claustrophobia, - Patients with severely reduced general condition and/or problems/pain when lying on their backs, so that waiting time and further lying time may not be tolerated, - Exclusion criteria according to Radiation Protection Ordinance, - Limited capacity of the patient to give consent.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Definition of an optimal time of examination for complementary late PET/CT in different oncological diseases. | — |
Secondary
| Measure | Time frame |
|---|---|
| - Differentiation between tissues with nonspecific and/or inflammation-related radiotracer uptake and tissues with tumor-associated radiotracer uptake, - Investigation of physiological late radiotracer enrichment of parenchymal reference organs (liver, spleen) versus radiotracer enrichment of parenchymal tumors with the aim of improving the "lesion-to-background" ratio, - More specific assessment of treatment response of chemotherapies, immunotherapies and -modulators, radionuclide therapies, and radiotherapies, - Investigation of progression-free survival and evaluation of (semi)-quantitative PET parameters with prognostic value, - Investigation of dosimetric aspects of late PET acquisition. | — |
Countries
Germany
Contacts
Public ContactChristian Reinert
Universitätsklinikum Tübingen, Radiologie, Diagnostische & Inerventionelle Radiologie
Outcome results
None listed